Concord Biotech Limited (BOM:543960)

Concord Biotech Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	2,824	2,609	3,716	3,081	2,401	1,749
Depreciation & Amortization	747.66	744.58	543.61	535.43	538.94	498.96
Other Amortization	0.01	0.01	0.13	0.49	1.39	1.55
Loss (Gain) From Sale of Assets	-2.93	-0.13	2.25	-0.12	0.94	0.34
Loss (Gain) From Sale of Investments	-220.83	-211.28	-222.64	-140.65	-37.17	-52.3
Loss (Gain) on Equity Investments	2.56	-29.09	13.22	-33.71	-19.59	36.38
Provision & Write-off of Bad Debts	28.66	27.58	17.84	6.69	0.92	-3.46
Other Operating Activities	-99.16	-332.69	81.91	17.31	96.59	71.19
Change in Accounts Receivable	-112.15	704.53	-1,708	-786.6	-430.97	-527.69
Change in Inventory	-1,215	-866.89	-317.13	43.61	-172.27	-415.12
Change in Accounts Payable	281.55	-85.2	220.89	-112.87	98.81	365.35
Change in Other Net Operating Assets	605.33	108.33	96.54	44.06	-18.42	356.91
Operating Cash Flow	2,840	2,669	2,445	2,655	2,460	2,081
Operating Cash Flow Growth	16.14%	9.15%	-7.89%	7.91%	18.19%	24.77%

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-1,016	-951.51	-1,112	-856.89	-1,451	-1,555
Sale of Property, Plant & Equipment	3.55	1	1.99	1.75	0.25	0.56
Investment in Securities	-1,152	-500.71	-520.08	-718.69	-184.76	395.22
Other Investing Activities	16.97	23.98	29.95	27.73	55.85	41.4
Investing Cash Flow	-2,148	-1,427	-1,600	-1,546	-1,580	-1,118

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Repaid	-	-3.81	-58.49	-	-43.37	-
Long-Term Debt Repaid	-	-2.73	-8.97	-265.04	-265.96	-266.56
Lease Payments	1.43	-2.73	-8.97	-14.98	-15.96	-16.54
Total Debt Repaid	1.43	-6.54	-67.45	-265.04	-309.33	-266.56
Net Debt Issued (Repaid)	1.43	-6.54	-67.45	-265.04	-309.33	-266.56
Common Dividends Paid	-789.87	-1,119	-915.39	-714.53	-535.64	-705.21
Other Financing Activities	-1.74	-2.83	-4.84	-12.58	-7.23	-22.26
Financing Cash Flow	-790.18	-1,129	-987.68	-992.15	-852.19	-994.02

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Miscellaneous Cash Flow Adjustments	-	-	-	-0	-	-14.29
Net Cash Flow	-97.65	112.82	-142.38	116.43	28.32	-44.77

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	1,824	1,717	1,333	1,798	1,009	526.36
Free Cash Flow Growth	40.64%	28.79%	-25.83%	78.14%	91.72%	-
Free Cash Flow Margin	-	16.28%	11.11%	17.68%	11.83%	7.38%
Free Cash Flow Per Share	17.35	16.41	12.75	17.18	9.65	5.03
Levered Free Cash Flow	-	1,374	943.22	1,178	505.95	188.91
Unlevered Free Cash Flow	-	1,375	946.53	1,194	534.14	223.18
Free Cash Flow After Leases	1,825	1,715	1,324	1,783	993.21	509.82

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	2.27	2.83	6.33	26.5	39.58	53.15
Cash Income Tax Paid	918.21	1,004	1,094	1,033	702.77	607.85
Change in Working Capital	-440.37	-139.23	-1,708	-811.8	-522.86	-220.55

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 29, 2026

Data Sources Report a data error